Gallery
- PM Modi visit USAOnly the mirror in my washroom and phone gallery see the crazy me : Sara KhanKarnataka rain fury: Photos of flooded streets, uprooted treesCannes 2022: Deepika Padukone stuns at the French Riviera in Sabyasachi outfitRanbir Kapoor And Alia Bhatt's Wedding Pics - Sealed With A KissOscars 2022: Every Academy Award WinnerShane Warne (1969-2022): Australian cricket legend's life in picturesPhotos: What Russia's invasion of Ukraine looks like on the groundLata Mangeshkar (1929-2022): A pictorial tribute to the 'Nightingale of India'PM Modi unveils 216-feet tall Statue of Equality in Hyderabad (PHOTOS)
Jakub Mensik overcame rain and an opponent chasing history when he stunned six-time champi
- KIPG: Son of a vegetable vendor, Bihar’s Jhandu Kumar eyes Worlds, 2028 Paralympics
- Hardik Singh credits hard work and team unity for receiving HI Midfielder of the Year award
- Djokovic, Alcaraz land in same half of Miami draw
- India to host 2nd Asian Yogasana Championships from March 29 to 31
- FA Cup: AFC Bournemouth secure 5-4 penalty shootout win vs Wolves to reach QF
Covaxin can deal with new Covid strains too: Bharat Biotech Last Updated : 30 Dec 2020 02:16:41 AM IST Covaxin c Bharat Biotech said on Tuesday that its vaccine candidate, Covaxin, will be effective in dealing with new strains of coronavirus.
Bharat Biotech Chairman and Managing Director Krishna Ella said the protein components of inactive Covaxin will take care of mutations.His comments came amid growing concerns over new strains of coronavirus SARS-CoV-2, especially the variant that was detected recently in the UK.Krishna Ella, who was delivering the ninth Dr Manohar V.N. Shirodkar Memorial Lecture organised by the Telangana Academy of Sciences, observed that that any virus is expected to have a lot of mutation.Hyderabad-based Bharat Biotech is developing Covaxin in collaboration with the Indian Council of Medical Research (ICMR). It has completed phase 1 and 2 clinical trials. The phase 3 efficacy trials of Covaxin were in progress with 20,000 volunteers, Ella said.The leading vaccine maker is also developing a single-dose nasal vaccine for Covid-19.In his lecture on "Innovation in Public Health - Our Journey," Ella said there were 40,000 unknown viruses and 10,000 zoonotic viruses and there was a need to focus on neglected and unknown diseases that could become global pandemics in future."All neglected diseases start from developing countries. Americans and Europeans are scared of us because these neglected diseases can turn into pandemics," he said.IANS Hyderabad For Latest Updates Please-
Join us on
Follow us on
172.31.16.186